Potential Early Detection for Crohn’s Disease via Blood Test

A recent study suggests that a straightforward blood test might detect Crohn’s disease years before any symptoms arise. This research, reported by SWNS, comes from Canadian scientists who believe their findings could allow for earlier diagnosis and possibly even prevention of this chronic inflammatory bowel disease (IBD).

The test specifically measures the immune system’s reaction to flagellin, a protein present in intestinal bacteria. Researchers observed that some individuals show an elevated immune response long before Crohn’s manifests.

The study was published in Clinical Gastroenterology and Hepatology and emphasizes the important interplay between gut bacteria and immune responses in the progression of the disease. Crohn’s disease, known for causing long-term gastrointestinal issues, leads to pain and fatigue, significantly affecting daily life. Alarmingly, the incidence of the disease among children has doubled since 1995.

Dr. Ken Kreitor, a clinical scientist at the University of Toronto, led this research. He noted that the presence of antibodies against flagellin before symptoms develop could mean that an immune response is a key factor triggering the disease. Enhanced understanding of this initial process might pave the way for better predictions, prevention, and treatments, as Kreitor observed, “No one has been cured yet, so we need to do better.”

The researchers sought to determine whether healthy individuals at risk for Crohn’s had these antibodies, finding that at least some did. This study is part of a larger project called Genetics, Environment, and Microbiology (GEM), which has been monitoring over 5,000 healthy relatives of Crohn’s patients since 2008 to gather genetic, biological, and environmental data for deeper insights on the disease’s development.

In this study, they focused on 381 first-degree relatives of Crohn’s patients; 77 went on to develop the disease. Strikingly, over 30% of these relatives had higher levels of antibody responses, especially among siblings, which points to shared environmental factors influencing risk.

Currently, 130 participants have progressed to Crohn’s disease, allowing researchers to analyze the disease’s early stages. The gap between collecting blood samples and diagnoses averaged nearly two years. Past GEM studies revealed inflammatory immune responses to gut bacteria can appear well before the onset of symptoms. In healthy individuals, the gut microbes coexist without issue, but Crohn’s patients often exhibit an abnormal immune response.

Furthermore, Dr. Sun-Ho Lee, a gastroenterologist in the study, mentioned that this research supports the potential for creating vaccines targeting flagellin for those at high risk of developing Crohn’s.

However, the study isn’t without limitations; it didn’t conduct experiments to clarify how the immune response directly leads to Crohn’s disease. Consequently, the researchers couldn’t pinpoint the biological processes that connect the immune response with disease development. They acknowledged ongoing efforts to validate and elaborate on these mechanisms.